BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35276290)

  • 1. Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo.
    Yue P; Zhu Y; Brotherton-Pleiss C; Fu W; Verma N; Chen J; Nakamura K; Chen W; Chen Y; Alonso-Valenteen F; Mikhael S; Medina-Kauwe L; Kershaw KM; Celeridad M; Pan S; Limpert AS; Sheffler DJ; Cosford NDP; Shiao SL; Tius MA; Lopez-Tapia F; Turkson J
    Cancer Lett; 2022 May; 534():215613. PubMed ID: 35276290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel Azetidine Amides as Potent Small-Molecule STAT3 Inhibitors.
    Brotherton-Pleiss C; Yue P; Zhu Y; Nakamura K; Chen W; Fu W; Kubota C; Chen J; Alonso-Valenteen F; Mikhael S; Medina-Kauwe L; Tius MA; Lopez-Tapia F; Turkson J
    J Med Chem; 2021 Jan; 64(1):695-710. PubMed ID: 33352047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer.
    Gong K; Jiao J; Xu C; Dong Y; Li D; He D; Zhao D; Yu J; Sun Y; Zhang W; Bai M; Duan Y
    J Nanobiotechnology; 2021 May; 19(1):165. PubMed ID: 34059068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
    Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
    Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
    Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J
    Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
    Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
    Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
    J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salidroside inhibits migration, invasion and angiogenesis of MDA‑MB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2.
    Kang DY; Sp N; Kim DH; Joung YH; Lee HG; Park YM; Yang YM
    Int J Oncol; 2018 Aug; 53(2):877-885. PubMed ID: 29901185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts.
    Zhong Y; Deng L; Shi S; Huang QY; Ou-Yang SM; Mo JS; Zhu K; Qu XM; Liu PQ; Wang YX; Zhang XL
    Acta Pharmacol Sin; 2022 Apr; 43(4):1013-1023. PubMed ID: 34267347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
    Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis.
    Yang Z; Xu H; Yang Y; Duan C; Zhang P; Wang Y; Fu K; Shen Y; Xu MX
    Breast Cancer Res Treat; 2023 Jan; 197(2):255-267. PubMed ID: 36369502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
    Garcia R; Bowman TL; Niu G; Yu H; Minton S; Muro-Cacho CA; Cox CE; Falcone R; Fairclough R; Parsons S; Laudano A; Gazit A; Levitzki A; Kraker A; Jove R
    Oncogene; 2001 May; 20(20):2499-513. PubMed ID: 11420660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
    Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
    Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
    Duan Z; Bradner JE; Greenberg E; Levine R; Foster R; Mahoney J; Seiden MV
    Clin Cancer Res; 2006 Nov; 12(22):6844-52. PubMed ID: 17121906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells.
    Liu L; Gaboriaud N; Vougogianopoulou K; Tian Y; Wu J; Wen W; Skaltsounis L; Jove R
    Cancer Biol Ther; 2014 Feb; 15(2):178-84. PubMed ID: 24100507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3.
    Dai X; Yin C; Guo G; Zhang Y; Zhao C; Qian J; Wang O; Zhang X; Liang G
    Toxicol Appl Pharmacol; 2018 Nov; 358():110-119. PubMed ID: 30195018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway.
    Yamashita N; Kondo M; Zhao S; Li W; Koike K; Nemoto K; Kanno Y
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2608-2612. PubMed ID: 28427809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.